Milestone Pharmaceuticals Announces NMPA Approval of Etripamil for PSVT

What Happened
On September 3, 2026, Milestone Pharmaceuticals, Inc. (MIST) announced via press release that China’s National Medical Products Administration (NMPA) has approved etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT) in adults. The company filed the press release as Exhibit 99.1 to its Form 8‑K under Item 8.01 (Other Events).

Key Details

• Approval granted by China’s National Medical Products Administration (NMPA).
• Indication: etripamil nasal spray for treatment of paroxysmal supraventricular tachycardia (PSVT) in adults.
• Press release dated September 3, 2026, filed as Exhibit 99.1 to the Form 8‑K.
• Form 8‑K disclosure category: Item 8.01 (Other Events); Exhibit list also included standard Inline XBRL cover page.

Why It Matters
Regulatory approval in China is a material milestone for Milestone’s lead product candidate, representing formal authorization by a major market regulator. This 8‑K reports the approval itself but does not provide financial details, commercialization plans, timing, or revenue estimates. Investors should watch for follow‑up disclosures from the company (e.g., filings or press releases) that provide details on launch plans, partnerships, pricing, or expected financial impact.